Baird Financial Services Likes Sarepta (SRPT) Stock

The Sarepta company building

Baird analyst Brian Skorney weighed in on Sarepta Therapeutics (SRPT), noting a pivotal design gets posted to Skorney is positive on the posting.

Skorney commented, “We think that the posting of the clinical trial to is an indication that the company and FDA have agreed on trial design. The study itself is in line with the company’s previous guidance and we believe should remove any overhang on trial design and timing. We believe the results will be overwhelmingly positive, putting them on track for 2020 BLA submission.”

The firm reiterated an Outperform rating and price target of $202.



Please enter your comment!
Please enter your name here